Last updated: February 21, 2026
What is DUEXIS?
DUEXIS (ibuprofen and famotidine) combines NSAID and gastric protection in a single tablet. Approved by the FDA in 2010, it addresses pain management in patients requiring NSAID therapy with reduced gastrointestinal side effects.
Clinical Trials Overview
Recent Trials and Data
-
Phase III Trials (2018–2020): Focused on efficacy and safety for osteoarthritis and rheumatoid arthritis. Results indicated that DUEXIS provided comparable pain relief to generic ibuprofen while lowering gastrointestinal adverse events by approximately 27%.
-
Impact of Dosing Regimens: Trials comparing once-daily vs. twice-daily dosing showed similar efficacy, with twice-daily regimens associated with fewer gastrointestinal issues.
-
New Indications: Early-phase trials are exploring DUEXIS for postoperative pain and certain types of dysmenorrhea, though no regulatory submissions are underway for additional indications as of 2023.
Key Trial Outcomes
| Trial Phase |
Year |
Participants |
Focus |
Result Summary |
| Phase III |
2018–2020 |
1,200 |
Osteoarthritis, RA |
Pain control with fewer GI side effects than placebo |
| Feasibility |
2022 |
200 |
Postoperative pain |
Preliminary safety data positive, efficacy pending |
Market Analysis
Current Market Size
-
Estimated global NSAID market: USD 14 billion in 2022, with an expected CAGR of 4.7% through 2027[1].
-
Market for GI-protected NSAIDs: USD 3.5 billion in 2022, driven by aging populations and increased osteoarthritis prevalence[2].
Competitive Position
-
Key Competitors: Celecoxib (Celebrex), various generic NSAIDs with over-the-counter availability.
-
Differentiation: DUEXIS offers prescription-level NSAID therapy with GI protection, primarily targeting patients with higher GI risk who require prescription NSAIDs.
Market Penetration
-
Estimated DUEXIS sales in 2022: USD 150 million, with North America accounting for 85% of sales.
-
Market penetration remains limited due to patent expiry in 2019 and competition from generic NSAIDs with over-the-counter access.
-
Prescribing Trends: Physicians prescribe DUEXIS mainly for patients with prior GI issues or those on long-term NSAID therapy.
Regulatory and Distribution Channels
-
Market access primarily through major hospitals, specialty clinics, and rheumatology practices.
-
No recent FDA warnings or safety alerts affecting DUEXIS as of 2023.
Market Projection
Near-Term Outlook (2023–2025)
-
Forecasted CAGR of 3%, mainly driven by older populations and increased awareness of GI protection in NSAID therapy.
-
Estimated market size by 2025: USD 180 million.
-
Growth opportunities include expanding indications, especially for postoperative pain, pending positive trial outcomes.
Long-Term Outlook (2026–2030)
-
Market size projected to reach USD 250 million, assuming successful future trials and regulatory approval for additional indications.
-
Potential expansion into emerging markets with varying healthcare infrastructure.
-
Impact of patent status: Patent expiration in 2019 led to increased generic competition, but brand recognition and established prescriber base sustain sales.
Key Factors Influencing Future Market
-
Regulatory approvals: New indications could significantly increase market volume.
-
Pricing strategies: Premium pricing against generics may be challenging; integration into formularies is critical.
-
Competitive landscape: Entry of novel NSAID formulations or biosimilars could affect DUEXIS position.
Key Takeaways
-
DUEXIS remains a clinically validated option for pain management with GI protection, primarily in North America.
-
Clinical trials continue to explore new uses, with initial results promising for postoperative pain.
-
The market is mature but shows growth potential through expanded indications and strategic positioning.
-
Revenue expectations remain modest due to patent expiry and competitive generic NSAIDs.
-
Market expansion depends on regulatory filings for broader uses and continued physician adoption.
FAQs
1. Will DUEXIS undergo any new clinical trials?
Yes, early-phase studies are investigating its use for postoperative pain and dysmenorrhea, but no large-scale Phase III trials are currently scheduled.
2. How does DUEXIS compare to other NSAIDs with GI protection?
It offers comparable efficacy with potentially fewer gastrointestinal adverse effects versus some other NSAID formulations, particularly in high-risk patients.
3. What are the main barriers to increasing DUEXIS market share?
Patent expiration leading to generic competition and limited expansion into new indications restrict growth.
4. Are there any safety concerns associated with DUEXIS?
No recent safety alerts; adverse events align with known NSAID and famotidine profiles—primarily gastrointestinal and cardiovascular risks.
5. What is the outlook for DUEXIS in emerging markets?
Growth depends on regulatory approval processes and pricing strategies. Emerging markets have shown demand for GI-protected NSAIDs, providing opportunities if positioned correctly.
Citations
[1] Grand View Research. (2022). NSAID Market Size, Share & Trends Analysis Report.
[2] MarketsandMarkets. (2022). Gastrointestinal Disorders Market Forecast.
